Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A novel Raji-Burkitt's lymphoma model for preclinical and mechanistic evaluation of CD52-targeted immunotherapeutic agents.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Jan 2008

Lapalombella Rosa, Zhao Xiaobin, Triantafillou Georgia, Yu Bo, Jin Yan, Lozanski Gerard, Cheney Carolyn, Heerema Nyla, Jarjoura David, Lehman Amy, Lee L James, Marcucci Guido, Lee Robert J, Caligiuri Michael A, Muthusamy Natarajan, Byrd John C

Abstract excerpt

PURPOSE: To date, efforts to study CD52-targeted therapies, such as alemtuzumab, have been limited due to the lack of stable CD52 expressing transformed B-cell lines and animal models. We describe generation and utilization of cell lines that stably express CD52 both in vitro and in vivo. EXPERIMENTAL DESIGN: By limiting dilution, we have established several clones of Raji-Burkitt's lymphoma cell line that...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized
Share to Antibodies, Monoclonal, Murine-Derived

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antibodies, Neoplasm

Share to Burkitt Lymphoma

Share to Leukemia, Lymphocytic, Chronic, B-Cell

Share to Liposomes

Share to Mice, SCID

Share to Rituximab

Source

Identifiers

PMID: 18223233
DOI: 10.1158/1078-0432.CCR-07-1006

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A novel Raji-Burkitt's lymphoma model for preclinical and mechanistic evaluation of CD52-targeted immunotherapeutic agents.PMID 18223233Read ↗

The Human CD38 Monoclonal Antibody Daratumumab Shows Antitumor Activity and Hampers Leukemia–Microenvironment Interactions in Chronic Lymphocytic LeukemiaSemantic proximity Read ↗

History and Classification of Human Leukemia-Lymphoma Cell LinesSemantic proximity Read ↗

Leukemia-lymphoma cell lines as model systems for hematopoietic researchSemantic proximity Read ↗

Complement-Induced Cell Death by Rituximab Depends on CD20 Expression Level and Acts Complementary to Antibody-Dependent Cellular CytotoxicitySemantic proximity Read ↗

Therapeutic Potential and Challenges of Targeting Receptor Tyrosine Kinase ROR1 with Monoclonal Antibodies in B-Cell MalignanciesSemantic proximity Read ↗

Radio-immunotherapy by 188Re-antiCD20 and stable silencing of IGF-IR in Raji cells, new insight in treatment of lymphomaSemantic proximity Read ↗

High reproducible ADCC analysis revealed a competitive relation between ADCC and CDC and differences between FcγRllla polymorphism.Semantic proximity Read ↗

Free circulating soluble CD52 as a tumor marker in chronic lymphocytic leukemia and its implication in therapy with anti-CD52 antibodies.Semantic proximity Read ↗

A three dimensional human immune-tumor cell model reveals the importance of isotypes in antibody-based immunotherapySemantic proximity Read ↗

Cellular Cytotoxicity of Next-Generation CD20 Monoclonal AntibodiesSemantic proximity Read ↗

CD38 as a Therapeutic TargetSemantic proximity Read ↗

The in vivo mechanism of action of CD20 monoclonal antibodies depends on local tumor burdenSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.